Vactosertib, a Novel, Orally Bioavailable Activin Receptor-Like Kinase 5 Inhibitor, Promotes Regression of Fibrotic Plaques in a Rat Model of Peyronie's Disease.
Kang-Moon SongDoo Yong ChungMin-Ji ChoiKalyan GhatakNguyen Nhat MinhLimanjaya AnitaMi Hye KwonJiYeon OckGuo Nan YinDae Kee KimJi Kan RyuJun Kyu SuhPublished in: The world journal of men's health (2019)
In view of the critical role of TGF-β and the Smad pathway in the pathogenesis of PD, inhibition of this pathway with an ALK5 inhibitor may represent a novel, targeted therapy for PD.